Management and Surveillance of Choledochal Cysts and Caroli Disease

Classification & Malignancy Risk

Type I choledochal cysts carry an approximately 7 % incidence of cholangiocarcinoma, underscoring a high malignant potential. 1
Type IV A cysts (combined intra‑ and extra‑hepatic disease) share the greatest predisposition to malignancy together with Type I lesions. 1
Isolated intra‑hepatic bile‑duct dilatation (Caroli disease) is defined as segmental saccular or fusiform dilatation of intra‑hepatic ducts. 3
Caroli disease must be differentiated from Caroli syndrome, which is associated with congenital hepatic fibrosis and renal cystic disease. 3

Complete cyst excision combined with cholecystectomy is the primary operative strategy for Types I, II, and IV choledochal cysts. 1
Biliary‑enteric reconstruction is performed with a Roux‑en‑Y hepaticojejunostomy to restore bile flow and minimize reflux. 1
When Type IV A involves intra‑hepatic cysts, a hepaticoenterostomy at the porta hepatis with partial resection of the intra‑hepatic cyst wall is recommended. 1

Acute complications such as cholangitis or sepsis should be controlled with broad‑spectrum antibiotics (e.g., third‑generation cephalosporins, ureidopenicillins, carbapenems, or fluoroquinolones) before definitive surgery. 1
In patients with septic shock or failure of medical therapy, urgent biliary decompression via ERCP‑guided stenting within 24 hours is advised. 1
For biliary obstruction without systemic infection, ERCP with sphincterotomy and placement of a temporary plastic stent serves as a bridge to definitive surgery. 1

Magnetic resonance cholangiopancreatography (MRCP) with contrast‑enhanced sequences is the preferred, non‑invasive imaging modality for confirming Caroli disease. 4
The characteristic “central dot sign” (fibrovascular bundles within dilated ducts) on MRCP is pathognomonic for Caroli disease. 3
Liver stiffness measurement by elastography helps assess underlying fibrosis and distinguishes Caroli disease from Caroli syndrome. 4
Diagnostic ERCP should be avoided because it markedly increases the risk of biliary infection. 4
Ursodeoxycholic acid can improve patient‑reported quality of life but does not extend survival in Caroli disease. 1
In Caroli syndrome with portal hypertension, non‑selective beta‑blockers are recommended for primary variceal prophylaxis. 4
Endoscopic variceal ligation is employed for acute variceal bleeding when required. 4
Localized disease with recurrent cholangitis or liver abscesses may be treated with hepatic resection. 5
Asymptomatic, isolated Caroli disease does not warrant surgical intervention. 5

Lifelong surveillance is mandatory because malignancy risk persists after cyst excision. 1
Years 1‑20 after resection:
- Annual liver function tests and CA 19‑9 measurement.
- Biannual abdominal ultrasound.
- Yearly MRCP for patients with Caroli disease or syndrome.
- (All components supported by guideline recommendations.) 1
After 20 years:
- Liver function tests and CA 19‑9 every 2 years.
- Ultrasound every 3 years. 1
The median incidence of metachronous malignancy after cyst excision is 5.6 % (range 0.7‑40 %). 2
Cholangiocarcinoma prevalence in Caroli disease is 7 % compared with 0.05 % in the general population. 4

MRCP is superior to CT for accurate delineation of the biliary tree and should be the imaging modality of choice. 1
Incomplete cyst excision leaves residual malignant potential and must be avoided. 1
Simple cyst drainage or cyst‑enteric anastomosis without excision is inadequate for definitive management. 2
Primary choledochorraphy is associated with higher anastomotic stricture rates and does not eliminate cancer risk. 2
Reliance on CA 19‑9 alone for cholangiocarcinoma screening in Caroli disease has poor diagnostic performance; it should be combined with imaging and clinical assessment. 4